19 results about "Total cholesterol" patented technology

The application relates to the field of biological medicine, and particularly relates to application of kaempferol-3-O-acacia di-saccharide-7-O-rhamnose glycoside in preparation of a medicine for preventing and / or treating diseases related to glycolipid metabolism disorder. The compound or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof can be used for treating diseases such as type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia and non-alcoholic fatty liver disease. The compound can significantly reduce intracellular glucose, triglyceride and total cholesterol levels, and can play a role by activating an AKT signal pathway, so as to improve glycolipid metabolism disorder and has potential clinical application value.

The application belongs to the technical field of biological medicine, and particularly relates to application of a GCN2 kinase inhibitor in preparation of a drug for treating heart failure with preserved ejection fraction. 18 H 12 ClF2N5O3S, the inhibitor can inhibit the activity of GCN2 kinase, and exhibits significant therapeutic effect in a disease model: can obviously improve ventricular diastolic function (E / E' ratio is reduced), reduce the level of heart failure markers, reduce cardiomyocyte hypertrophy and interstitial fibrosis, inhibit the expression of oxidative stress level and inflammatory factors, reduce the accumulation of triglyceride and total cholesterol in myocardium and serum, and improve obesity-related insulin resistance and metabolic disorder. The application provides a novel targeted treatment strategy and candidate drug for heart failure with preserved ejection fraction.

The invention relates to the technical field of coreopsis tinctoria refined components and preparation and application, and provides a coreopsis tinctoria refined component and a preparation method and application thereof.The coreopsis tinctoria refined component comprises, by mass, 11 specific components of phenolic acids, flavonol, flavanol and flavonoid, and the 11 specific components comprise, by mass, 2 parts of gallic acid, 1 part of potassium sorbate, 1 part of potassium sorbate, 1 part of potassium sorbate and 1 part of potassium sorbate. The health-care food is prepared from the following raw materials in parts by weight: 3 parts of chlorogenic acid, 14 parts of quercetin, 18 parts of catechin, 5 parts of citric acid, 2-3 parts of procyanidine B, 3 parts of (+)-epicatechin, 1-31 parts of 31 parts of procyanidine C, 14 parts of rutin, 4 parts of camphanol-3-O-rutinoside and 2 parts of isorhamnetin-3-O-rutinoside. The snow chrysanthemum is Changbai Mountain snow chrysanthemum. Animal experiments show that the refined component can significantly reduce the content of total cholesterol and triglyceride in serum of a high-fat model rat, the specific component with blood fat regulating activity is prepared from Changbai Mountain snow chrysanthemum, and a new choice is provided for non-drug intervention of dyslipidemia.

1. The name of the design product: multi-parameter detector. 2. The use of the design product: for the detection of blood sugar, total cholesterol, triglyceride, uric acid. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The application discloses application of calyculostero in preparation of blood sugar reducing drugs, and belongs to the technical field of pharmacological action of calyculostero. Experimental results show that the calyculostero can inhibit the activity of pancreatic alpha-amylase (IC50 is 4.34+ / -1.10 ug / mL) in a dose-dependent manner, reduce postprandial blood sugar, and improve sugar tolerance, reduce fasting blood sugar, improve total cholesterol and triglyceride levels, and reduce histopathological changes of liver, pancreas and kidney in long-term intervention, and has no obvious hepatotoxicity. The calyculostero can be used alone or together with a pharmaceutically acceptable excipient to prepare a pharmaceutical composition, and is used for reducing blood sugar or treating diabetes, and the dosage form includes oral preparations, injections and the like. The application provides a new natural medicine selection for drug treatment of diabetes.

The application discloses a plant lactobacillus gasseri strain capable of transforming ginsenoside and cassia glycoside, and application of the strain in lipid reduction and alleviation of fatty liver, and belongs to the fields of microbial technology, medicine and functional food. The core feature of the strain is that the strain can not only transform ginsenoside Rb1 into ginsenoside Rd with higher activity, but also transform cassia glycoside into cassia glycoside base, thereby improving the efficacy. The animal experiment proves that the strain and the corresponding substrate are combined to play a better role in lipid reduction and liver protection: the serum total cholesterol and triglyceride levels of high-fat diet mice can be effectively reduced, and the liver weight, liver lipid deposition and liver tissue fatty degeneration can be reduced and improved. The strain provides a new core strain and technical scheme for developing microecological preparations for preventing and / or assisting in treating hyperlipidemia, non-alcoholic fatty liver and other metabolic diseases.

The present application relates to the technical field of biotechnology, and discloses a plant Lactobacillus plantarum XKFY202518 and application of the plant Lactobacillus plantarum XKFY202518 in preparation of a type 2 diabetes auxiliary preparation for improving insulin resistance and regulating blood lipid, the plant Lactobacillus plantarum XKFY202518 has a preservation number of CGMCC No.34745 in China General Microbiological Culture Collection Center, and a preservation date of June 3, 2025.The plant Lactobacillus plantarum XKFY202518 separated by the present application can effectively reduce the fasting blood glucose level, insulin level, total cholesterol level, triglyceride level, low-density lipoprotein cholesterol level, alanine aminotransferase level and aspartate aminotransferase level of a diabetic mouse, and increase the high-density lipoprotein cholesterol level of the mouse serum, thereby improving the hyperglycemia and hyperlipidemia symptoms of a type 2 diabetes mouse.

This invention discloses a dry chemical reagent for total cholesterol detection, comprising a diffusion layer, a spacer layer, and a reagent layer sequentially overlapped. The diffusion layer includes reflective particles, a binder, a surfactant, cholesterol esterase, and cholesterol oxidase. The reagent layer includes a carrier, horseradish peroxidase, an indicator composition, and a buffer solution. The dry chemical detection reagent of this invention employs a coating method, layering a premixed homogeneous slurry onto a support layer. A spacer layer blocks interlayer interference, and phenolic substances replace photosensitizers as chromogens, combined with a specific ratio of substrate and buffer system. The multi-layered, spacer-free, low-interference vertical detection system constructed by this invention significantly improves the repeatability, accuracy, and stability of the detection reagent.

The application belongs to the technical field of medicine, and particularly relates to the use of icariin in the preparation of lipid-lowering drugs with muscle protection. In view of the adverse reactions such as myalgia and myositis caused by the existing statins in the lipid-lowering process, the muscle protection effect of icariin in the lipid-lowering process is evaluated by constructing a high-fat cell model and a high-fat Caenorhabditis elegans model. It is found through research that icariin can significantly reduce the content of triglyceride, total cholesterol and lipid droplet accumulation in high-fat cells, reduce the content of triglyceride and lipid droplet accumulation in high-fat C. elegans, and prolong the lifespan of high-fat C. elegans. Further research shows that icariin can improve the muscle state of high-fat C. elegans while lowering lipid, and the specific performance is the enhancement of the movement ability of C. elegans and the maintenance of the structural integrity of body wall muscle fibers. The application discloses the unique advantage of icariin in the lipid-lowering process, that is, the muscle protection effect, and can solve the adverse reactions such as myalgia and myositis caused by the existing statins, and has an important clinical application prospect.

The application belongs to the field of biological medicine research and development, and particularly relates to application of umbilical cord mesenchymal stem cell-derived vascular endothelial precursor cells in preparation of medicines for preventing and treating atherosclerosis. By interfering with expression of related factors in a pyroptosis inflammatory signaling pathway of NLRP3, ASC, Caspase-1, GSDMD, IL-1β and IL-18 at a transcription and protein level, the serum triglyceride concentration, total cholesterol concentration and low-density lipoprotein concentration can be reduced, the serum oxidized low-density lipoprotein and oxygen free radical concentration can be reduced, the serum high-density lipoprotein concentration can be increased, and the atherosclerotic plaque area can be reduced and cell apoptosis in the atheromatous plaque can be inhibited.

The present application relates to a kind of feed additive for improving fatty liver of post- laying hen and its preparation method and application method, belong to livestock and poultry feed processing technical field.For the single component additive effect of post- laying hen fatty liver is limited, and lack of the plant combination with synergistic effect screened from local characteristic plant resources.The feed additive provided by the present application comprises the ethanol extract of the mixture of small Xianggou root, tea leaf piece and San Ye Qing tuber, and the weight ratio of small Xianggou root, tea leaf piece and San Ye Qing tuber is (4.0-4.2) : (3.3-3.4) : 2.6.The additive can systematically improve the liver lipid metabolism of post- laying hen, reduce the triglyceride and total cholesterol levels in liver and serum, relieve fatty liver hemorrhagic syndrome, and improve egg production rate and egg quality.The additive is mainly used for post- laying hen feed to improve liver health and maintain production performance.

The application discloses a plant lactobacillus CCFM1486 transformed with siania glycoside, which can enhance lipid-lowering, weight loss and relieve liver lipid accumulation, and application thereof. The strain is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No: 66133. The core of the application is that the strain exhibits a significant synergistic effect when combined with siania glycoside: not only can it efficiently generate siania glycoside, but also can significantly inhibit weight gain caused by high-fat diet, reduce serum total cholesterol and triglyceride levels, and target to reduce liver lipid deposition and improve liver tissue fatty degeneration, and the effect is better than that of using siania glycoside alone. The live bacteria, fermented siania glycoside and combined preparation prepared based on the strain can be used for developing innovative products for preventing and / or assisting in treating obesity, hyperlipidemia and non-alcoholic fatty liver.

This invention belongs to the field of biomedical technology, specifically relating to an isoflavone compound, its preparation method, and its application. This compound is derived from *Rotenoporosis capillaris* (a type of vine). Derris eriocarpa The stem of *Derris fusiforme* was analyzed using 1D and 2D nuclear magnetic resonance (NMR) spectra (1H NMR, 1C NMR, and high-resolution mass spectrometry), and its structural formula is shown below: Chemical name: 5-hydroxy-6-(2"-hydroxy-3"-methylbut-3"-enyl)-3-(4'-hydroxyphenyl)-7-methoxyisoflavone. Screening using the Sci-finder database revealed that this compound is a novel isoflavone, isolated for the first time from *Derris fusiforme*. Lipid-lowering activity experiments showed that at the same drug concentration (25 μg / mL) as the positive control, it significantly reduced intracellular total cholesterol and triglyceride levels. p <0.001). Therefore, this novel isoflavone compound can be used to prepare drugs, health products, functional foods, or special medical foods for the prevention or treatment of hypertriglyceridemia, hyperlipidemia, obesity, or metabolic syndrome.

The application belongs to the field of new use of medicines, and more particularly relates to application of Darapladib in preparation of medicines for preventing and treating metabolic dysfunction related fatty hepatitis. The application firstly finds that after treatment by Darapladib, the liver weight, liver / body ratio, serum total cholesterol, steatosis, ballooning, inflammatory infiltration and collagen deposition of MASH model mice are significantly reduced. The application expands the traditional use of Darapladib in cardiovascular diseases, and provides a new treatment strategy for MASH.

The present application relates to the technical field of functional composition, in particular to a composition containing Zanthoxylum bungeanum seed oil with the function of reducing three high and its preparation method and application. The composition comprises core material and successively wrapped outermost layer controlled release material, intermediate layer controlled release material and outermost layer controlled release material of the core material, the core material comprises active ingredient and antioxidant, the active ingredient is a mixture of Zanthoxylum bungeanum seed oil, hydroxyl-alpha-sanshool and nervonic acid concentrate, the outermost layer controlled release material, the intermediate layer controlled release material and the outermost layer controlled release material are used to control the release rate of the active ingredient in the stomach to be not more than 5% / h, the release amount in the small intestine to be not more than 30%, the rest is released in the colon and the release time in the colon is more than 8h. The composition of the present application solves the problem that the existing oil product with the function of regulating three high lacks multi-target synergistic regulation in the mechanism of action, and the regulating effect of three high is poor, and can be used in functional food, pharmaceutical preparation for regulating blood pressure, blood sugar or / and blood lipid.

This invention relates to an abalone active peptide with the amino acid sequence DYPRPW. The preparation method is as follows: Abalone viscera are enzymatically hydrolyzed using alkaline protease to obtain an enzymatic hydrolysate; the enzyme is then inactivated after hydrolysis. The hydrolysate is centrifuged, coarsely filtered, and ultrafiltered to collect multiple polypeptides with a molecular weight less than 1 kDa, which are then freeze-dried into powder. The freeze-dried polypeptide powders are sequenced to obtain multiple polypeptide sequences; repetitive sequences are deleted, and multiple non-repetitive polypeptides are screened. Using the protein HMGR as a receptor, the obtained polypeptides are virtually screened using docking software, and the polypeptides with the highest docking scores are selected for solid-phase synthesis to obtain the abalone active peptide. This invention's abalone active peptide can effectively inhibit the accumulation of total cholesterol and total triglycerides in cells, exhibits a high inhibition rate of cholesterol micelle solubility, and has lipid-lowering effects. It can be used to prepare adjuvant lipid-lowering drugs, and compared with traditional lipid-lowering drugs, it has the advantages of high specificity and fewer toxic side effects.

The application discloses a health wine with the functions of reducing triglyceride, total cholesterol and blood pressure and a preparation method thereof. Red highland corn and bitter buckwheat are used as fermentation raw materials, and base wine is obtained through saccharification and distillation. The core of the method is that the residue of the raw material after distillation is subjected to two solid-state fermentations, and the ultrasonic-assisted extraction and percolation extraction technologies are combined to efficiently extract an extract liquid rich in active ingredients, which is accurately added into the base wine after concentration and freeze-drying. The method realizes multi-level utilization of the raw material, and significantly improves the extraction rate of functional components such as flavonoids and polysaccharides. The active ingredients in the product are added simultaneously, and the polysaccharides in pilose antler and the active ingredients in bitter buckwheat are synergistically enhanced. Animal experiments show that the health wine has the functions of reducing blood sugar, blood fat and blood pressure.

This invention discloses the application of Xinnaoning capsules in the preparation of drugs for treating non-alcoholic fatty liver disease (NAFLD), belonging to the field of pharmaceutical technology. Using a high-fat diet-induced NAFLD model in SD rats, this invention demonstrates that Xinnaoning capsules can significantly reduce liver and serum total cholesterol and triglyceride levels, lower alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to protect liver function, downregulate inflammatory factors such as tumor necrosis factor-α, interleukin-6, and interleukin-1β, improve insulin resistance, and alleviate hepatic steatosis and inflammatory damage in a dose-dependent manner, with higher doses showing better effects. This invention provides a safe, multi-target traditional Chinese medicine treatment for NAFLD, expands the clinical indications of Xinnaoning capsules, and has significant academic value and clinical application prospects.